Notícias e Atividades da Alvotech

Fusão, aquisição e financiamento envolvendo Alvotech.

• Alvotech acaba de anunciar uma arrecadação de fundos de 165 milhões de dólares. (publicado em 19 de junho de 2026).

Veja o organograma con seus 33 executivos principais

Biografias mais buscadas da Alvotech

• Lisa Graver, Chief Executive Officer
• Tomas Ekman, Director
• Arni Hardarson, Independent Director

Recentes movimentos de executivos em Alvotech

• Tanya Zharov, General Counsel, deixou a Companhia  (Notícia publicada em 4 de maio de 2026).
• Johan Van Der Putten, Vice President, Global Procurement, deixou a Companhia  (Notícia publicada em 6 de abril de 2026).
• Robert Wessman, Executive Chairman and Chief Executive Officer , deixará a Companhia em 31 de mar. de 2026  (Notícia publicada em 7 de janeiro de 2026).

Clique aqui para ver outras movimentos em Alvotech

Criar um alerta
para seguir os movimentos de executivos da Alvotech.

Alvotech possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Patrick Enright - Director da CuraSen Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Alvotech

• Transactions of Managers and Closely Associated Persons | Alvotech
• Alvotech further strengthens liquidity by securing term loan facility of $75 million | Alvotech
• Transactions of Managers and Closely Associated Persons | Alvotech
• Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement | Alvotech
• Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement | Alvotech
• Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares | Alvotech
• Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio® | Alvotech
• Transactions of Managers and Closely Associated Persons | Alvotech
• Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea® | Alvotech
• Alvotech to present at upcoming investor conferences in June | Alvotech
• View more press releases Close

Redes sociais sobre Alvotech

• Alvotech na Wikipedia, Google News e Yahoo Finance
• Alvotech na LinkedIn, X (Twitter) e YouTube